Peri-Procedural Infarction: More Frequent than and Not as Innocent as We Thought

Almost 30% of all patients experience some degree of myocardial injury after elective angioplasty, a statistic associated to an increase in cardiovascular events at 30 days and 1 year, according to this study recently published in Eur Heart J.

infarto peri-procedimientoThe study only included consecutive patients who underwent elective angioplasty with a negative troponin level at admission. The primary endpoint was defined as a composite of peri-procedural infarction (type 4a infarction), stent thrombosis (type 4b), and myocardial injury according to the third universal definition of infarction.

Multivariable analysis was performed to identify independent predictors of infarction and myocardial injury, and their relation to 30-day and 1-year events.


Read also: ACC 2018 | SECURE-PCI: High Dose of Statins pior PCI Could Help.


Among 1390 patients who underwent elective angioplasty, the primary endpoint was observed in 28.7% of cases, including 7.0% of type 4a infarction, 0.14% of type 4b infarction, and 21.6% of myocardial injury.

Independent risk factors were left main disease, total stent length >30 mm, multiple stenting, chronic kidney disease (estimated glomerular filtration rate <60 mL/min), and age >75 years old.

At 30 days, patients with peri-procedural infarction or myocardial injury had a higher rate of cardiovascular events (5.5% vs. 1.2%; p < 0.001), which was mainly driven by ischemic events (3.2% vs. 0.6%; p < 0.0001).


Read also: Surgery Seems Superior to Angioplasty in Young Patients.


At 1 year, the risk of events remained higher for patients with peri-procedural infarction or myocardial injury (p = 0.004).

Conclusion

Peri-procedural infarction and myocardial injury are frequent complications of elective angioplasty and are associated with an increase in cardiovascular events at 30 days and 1 year.

Original title: Periprocedural Myocardial Infarction and Injury in Elective Coronary Stenting.

Reference: Michel Zeitouni et al. Eur Heart J. 2018 Apr 1;39(13):1100-1109.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....